CD274 and squamous cell carcinoma: The proportion of patients aged ≥75 years, having an ECOG PS score of ≥2, squamous cell carcinoma, and PD-L1 expression <1% was higher in the present study than in the CheckMate 9LA (20) and CheckMate 227 (21) phase III trials.